Clinical Utility Of A Next-Generation Sequencing Panel For Acute Myeloid Leukemia Diagnostics

Next-generation-sequencing (NGS) has redefined the genetic landscape of acute myeloid leukemia (AML) providing new molecular markers for diagnostic and prognostic classifications. However, its application in the clinical setting is still challenging. We hypothesized that a 19-gene AML-targeted NGS panel could be a valid approach to obtain clinically relevant information. Thus, we assessed the ability of this panel to classify AML patients according to diagnostic and prognostic indexes in a cohort of 162 patients.

Source: Journal of Molecular Diagnostics - December 18, 2018 Category: Pathology Authors: Carmen M. Alonso, Marta Llop, Claudia Sargas, Laia Pedrola, Joaqu ín Panadero, David Hervás, José Cervera, Esperanza Such, Mariam Ibáñez, Rosa Ayala, Joaquín Martínez-López, Esther Onecha, Inmaculada de Juan, Sarai Palanca, David Martínez-Cuadró Tags: Regular Article Source Type: research